Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced the granting of non-statutory stock options to three new employees. The grants were made under the company's 2022 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). An aggregate of 130,800 options were granted to purchase shares of Fulcrum's common stock at an exercise price of $8.63 per share, which was the closing price on September 9, 2024, the grant effective date.
Each option has a ten-year term and vests over four years, with 25% vesting on the first anniversary of the employee's start date and an additional 6.25% vesting quarterly over the following three years, subject to continued employment.
Fulcrum Therapeutics (Nasdaq: FULC), una azienda biofarmaceutica in fase clinica, ha annunciato l'assegnazione di opzioni su azioni non statutarie a tre nuovi dipendenti. Le concessioni sono state effettuate nell'ambito del Piano di Incentivazione Azionaria per il 2022 dell'azienda, in conformità con la Regola di quotazione Nasdaq 5635(c)(4). Un totale di 130.800 opzioni sono state concesse per acquistare azioni ordinarie di Fulcrum a un prezzo di esercizio di $8,63 per azione, che era il prezzo di chiusura al 9 settembre 2024, data di entrata in vigore della concessione.
Ogni opzione ha un termine di dieci anni e si maturerà in quattro anni, con il 25% che matura al primo anniversario della data di assunzione del dipendente e un ulteriore 6,25% che matura trimestralmente nei successivi tre anni, a condizione di un'impiego continuativo.
Fulcrum Therapeutics (Nasdaq: FULC), una empresa biofarmacéutica en etapa clínica, ha anunciado la concesión de opciones sobre acciones no estatutarias a tres nuevos empleados. Las concesiones se realizaron bajo el Plan de Incentivo de Acciones por Inducción 2022 de la empresa, de acuerdo con la Regla de Listado Nasdaq 5635(c)(4). Se otorgaron un total de 130,800 opciones para comprar acciones ordinarias de Fulcrum a un precio de ejercicio de $8.63 por acción, que era el precio de cierre del 9 de septiembre de 2024, la fecha de efectividad de la concesión.
Cada opción tiene un plazo de diez años y se adquiere durante cuatro años, con el 25% adquiriéndose en el primer aniversario de la fecha de inicio del empleado y un adicional del 6.25% adquiriéndose trimestralmente durante los siguientes tres años, sujeto a la continuación del empleo.
Fulcrum Therapeutics (Nasdaq: FULC)는 임상 단계의 생명공학 회사로서 세 명의 새로운 직원에게 비정규 주식 옵션을 부여한다고 발표했습니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 회사의 2022 유도 주식 인센티브 계획에 따라 이루어졌습니다. 총 130,800개의 옵션이 Fulcrum의 보통주를 주당 $8.63의 행사가로 구매할 수 있도록 부여되었으며, 이는 2024년 9월 9일의 종가인 grant 유효일의 가격이었습니다.
각 옵션은 10년 기간을 가지며, 4년에 걸쳐 배분됩니다. 첫 번째 직원 근무일의 첫 번째 기념일에 25%가 배분되고, 이어지는 3년 동안 분기별로 6.25%가 추가로 배분되며, 계속 근무하는 조건이 있습니다.
Fulcrum Therapeutics (Nasdaq: FULC), une entreprise biopharmaceutique en phase clinique, a annoncé l'octroi d'options d'achat d'actions non statutaires à trois nouveaux employés. Les octrois ont été réalisés dans le cadre du Plan d'Incitation aux Actions de 2022 de l'entreprise, conformément à la Règle d'inscription Nasdaq 5635(c)(4). Un total de 130 800 options ont été accordées pour acheter des actions ordinaires de Fulcrum à un prix d'exercice de 8,63 $ par action, qui était le prix de clôture du 9 septembre 2024, la date d'entrée en vigueur de l'octroi.
Chaque option a une durée de dix ans et s'acquiert sur une période de quatre ans, avec 25 % qui s'acquièrent à la première date anniversaire du début de l'emploi et un supplémentaire de 6,25 % qui s'acquiert trimestriellement au cours des trois années suivantes, sous réserve d'un emploi continu.
Fulcrum Therapeutics (Nasdaq: FULC) ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das die Gewährung von nicht-statutären Aktienoptionen an drei neue Mitarbeiter angekündigt hat. Die Zuteilungen erfolgten im Rahmen des Aktienoptionsplans zur Anwerbung 2022 des Unternehmens gemäß der Nasdaq-Listing-Regel 5635(c)(4). Insgesamt wurden 130.800 Optionen zur Kauf von Aktien des Unternehmens zu einem Ausübungspreis von 8,63 $ pro Aktie gewährt, was dem Schlusskurs vom 9. September 2024, dem Datum der Wirksamkeit der Vergabe, entsprach.
Jede Option hat eine Laufzeit von zehn Jahren und wird über vier Jahre vestiert, wobei 25 % am ersten Jahrestag des Arbeitsbeginns des Mitarbeiters und zusätzlich 6,25 % vierteljährlich in den darauffolgenden drei Jahren vestiert werden, vorbehaltlich eines fortgesetzten Arbeitsverhältnisses.
- Fulcrum is attracting new talent, potentially strengthening its workforce
- The company is using stock options as a tool for employee retention and alignment with shareholder interests
- The issuance of stock options may lead to potential dilution for existing shareholders
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to three new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Fulcrum granted the new employees an aggregate of 130,800 options to purchase shares of the company’s common stock at an exercise price of
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
How many stock options did Fulcrum Therapeutics (FULC) grant to new employees?
What is the exercise price of the stock options granted by Fulcrum Therapeutics (FULC)?
What is the vesting schedule for the stock options granted by Fulcrum Therapeutics (FULC)?
Under which plan did Fulcrum Therapeutics (FULC) grant these stock options?
